Caroline Messer
Endocrinology, Diabetes & Metabolism · Mount Kisco, NYNPI 1386855047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $144,255 of the $175,451 with a category attached, or 82.2%. Novo Nordisk accounts for 80.0% of it on its own, with 58 other manufacturers making up the rest. Reporting peaked in 2021 at $68,350 and has fallen 95.9% since, to $2,821 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,189 payments — averaging $147.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$140K
- Mannkind Corporation$18K
- Lilly USA, LLC$3K
- Amgen$2K
- AbbVie$2K
- AstraZeneca$1K
- plus $10K from 53 others
What the payments were for
- Speaking & faculty fees$144,25582%
- Travel & lodging$5,7643%
- Food & beverage$25,28314%
- Education$720%
- Gifts$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$175,451 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 335 | $378,882 |
| OzempicSemaglutide | 174 | $237,578 |
| JardianceEmpagliflozin | 125 | $109,503 |
| TrulicityDulaglutide | 33 | $53,964 |
| JanuviaSitagliptin Phosphate | 76 | $41,432 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 13 | $32,969 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $25,621 |
| RybelsusSemaglutide | 24 | $22,688 |
| ProliaDenosumab | 12 | $20,410 |
| AfrezzaInsulin Regular, Human | 11 | $19,394 |
| XyostedTestosterone Enanthate | 26 | $16,208 |
| SynthroidLevothyroxine Sodium | 196 | $15,675 |
| FarxigaDapagliflozin Propanediol | 16 | $15,610 |
| TradjentaLinagliptin | 24 | $15,354 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $11,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,605 | $432,846368 claims |
| Novo NordiskOzempic, Rybelsus | $140,361 | $260,265198 claims |
| Boehringer IngelheimJardiance, Tradjenta | $183 | $124,857149 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,816 | $53,37825 claims |
| MerckJanuvia | $216 | $41,43276 claims |
| Mannkind CorporationAfrezza | $17,945 | $19,39411 claims |
| Antares Pharma, Inc.Xyosted | $568 | $16,20826 claims |
| AbbVieSynthroid, Armour Thyroid | $1,766 | $16,172214 claims |
| AstraZenecaFarxiga | $1,337 | $15,61016 claims |
| Johnson & JohnsonInvokana | $48 | $10,92814 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $356 | $1,944169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Mount Kisco
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.